Longs who held after FDA approval see Afrezza as a blockbuster. This is a slow launch without any PR or advertisement, and they haven't even manufactured enough Afrezza to meet any expectation of high volume. Thus, you have to wait for consumer advertisments and full launch. In the mean time, Afrezza is gaining traction, increasing scripts by factor of 50-100%.
Shorts on the other hand, was 70 million shares in the hole before FDA approval, so they hoped that Afrezza would get killed by the FDA. But it didn't, so now we have manipulation with 40+ more million shares used to manipulate price down. I think they dug themselves into their own graves.
The shorts attacked and we will see soon how many more shares they burned trying to control the price, from the last two weeks of trading. This worked well into SNY buying; they are getting a bargain compared to buyout price. In a few weeks, we will see what the shorts actually have been doing since Middle of May.
if it stays in the 4's, it is time to add more shares. We are at the bottom, time will get better and better with scripts#
you should short sell everything above zero then. Becareful, commision may cost more than share price.
out of 52 states, they got 4 scripts from each state? Just how many docs know about AFrezza? Did they send out 10 SNY reps to sell Afrezza?
This tells me that the number of docs prescribing Afrezza has been the same for 2 months. Something smells fishy here.
it doesn't mean anyuthing, looke at the share price and it's dirt cheap, so he changed his mind. Any logical person would, take it as that! don't read too much into it.
BTW that $1 million was at market (so the price is what they could get for Afrezza). Mankind produced $7.1 million at COST, at market would be much much higher.
that $1 million sell was only in the US. Perhaps they are stocking away for Euro or Asian launch, and samples all over the world. Spread the samples across the globe and get the docs familiarized before massive advertisement campaign to drive the patients to the docs.
We all know that Feuerstein and Shkrelli wanted afrezza to fail and these guys went as far as trying to convince the Fda to kill afrezza. Revenge?
Mnkd sent out $7.1 million of afrezza at cost but Sny only sold $1 million at market value, so where is the rest of the $7.1 million of afrezza, at cost? All samples? So, what's gonna happen when the samples run out? Will there be a huge surge in demand? Did Sny and Mnkd teamed up to kill shorts? They just opened up lines 2 and 3 to increase afrezza production. Stay tuned folks, shorts are about to get massively squeezed of a life time.
you are so American centric; you think America is the only country who can afford drugs. Did you know that China has exceeded the US is the world's biggest economy. BTW, the Chinese are coming over the US to buy our homes and properties. Developed Asian countries like Singapore, Taiwan, Hong Kong, and China can afford anything Americans can. Don't forget the Europeans!
even with Exubera, that flopped had better scripts number later, increasing every week because the number of docs exposed to Exubera education increased with time. NOt the same for AFrezza; SNY is intentionally keeping the number docs exposed to Afrezza the same from week 1
Think about it folks, why has the number of scripts been consistently about 200/wk? The only explanation is the number of docs prescibing has not changed week after week. That means SNY only are teaching a set number of docs; they have not increased the number of docs exposed to AFrezza at all. Theoretically the number of docs should increase with time and so as the scripts number, but why is the script # remaining the same week after week?. Something is shaddy here with sNY. buyout!!!
what you are saying makes sense but would MNKD and SNY be protected because they simply announced to the world that it would be "slow controlled launch"; this phrase allows a lot of wiggle room and possible foul play. But I am not a lawyer and I definitely could be wrong.
if you looked at the number of scripts/wk, it has been consistently around 200+- 25 every month since the beginning of the launch. This tells me that the number of docs writing these scripts have not changed. I would have to assume that if 1000 SNY reps are recruiting new docs every week, then the number of scripts should increase. So, what is SNY really doing?
My question is can the shorts sue Mnkd and SNY for setting up a trap? If that is the case, the shorts may initiate lawsuits accusing mnkd/sny of creating a false perception of a slow launch. What about those longs who bought in and got scared and sold off too early, can they sue mnkd/sny? Any corporate lawyers here?
true, that is the other problem with this slow controlled launch is that initially manufacturing facility only was with ONE line; they just opened 2 additional lines. You are right 300% increase in production, with 12 units available. I sense that they will advertise and work harder to reach out to more doctors; otherwise, they would not have opened 2 more production lines.
OR we may get a buyout offer quietly before advertisements and PR.